Minimal myocardial damage during coronary intervention is associated with impaired outcome

European Heart Journal

Volumn 20, Issue 15, 1999, Pages 1112-1119

  Simoons, M L ^a   Van den Brand, M ^a   Lincoff, M ^b   Harrington, R ^c   Van der Wieken, R ^d   Vahanian, A ^e   Rutsch, W ^f   Kootstra, J ^a   Boersma, E ^a   Califf, R M ^c   Topol, E ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LERNER RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY   (United States)

^d ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^e HÔPITAL TENON   (France)

^f HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Abciximab; Creatine kinase MB; Follow up; Myocardial infarction; PTCA

Indexed keywords

ABCIXIMAB; CREATINE KINASE; CREATINE KINASE MB; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST;

ANGIOCARDIOGRAPHY; ARTICLE; BYPASS SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART MUSCLE INJURY; HEART REINFARCTION; HEART SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVASCULARIZATION; STATISTICAL ANALYSIS; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CREATINE KINASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; ISOENZYMES; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033179511     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.1521     Document Type: Article

References (21)

1. The CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997; 349: 1429-35.
2. EPIC investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
3. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
4. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-53.
5. The IMPACT II investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997; 349: 1422-8.
6. Abdelmeguid AE, Whitlow PL, Sapp SK et al. Long-term outcome of transient, uncomplicated in-laboratory coronary artery closure. Circulation 1995; 91: 2733-41.
7. Abdelmeguid AE, Topol EJ, Whitlow PL et al. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996; 94: 1528-36.
8. Hong MK, Bucher TA, Wu H et al. CPK-MB elevation following successful saphenous vein graft angioplasty is associated with increased late mortality. Abstract 165 from the 70th Scientific Sessions AHA, 1997.
9. Cutlip DE, Clauhan M, Senerchia C, Ho KK, Balm D, Kuntz RE. Influence of myocardial infarction following otherwise successful coronary intervention on late mortality. Abstract 162 from the 70th Scientific Sessions AHA, 1997.
10. Abdelmeguid AE, Ellis SG, Sapp SK et al. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J 1996; 131: 1097-105.
11. Ohman EM, Tardiff BE. Periprocedural cardiac marker elevation after percutaneous coronary artery revascularization. Importance and implications. JAMA 1997; 277: 495-7.
12. Abdelmeguid AE, Topol EJ. The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures. Circulation 1996; 94: 3369-75.
13. Califf RM, Abelmeguid AE, Kuntz RE et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998; 31: 241-51.
14. Hamm CW, Reimers J, Ischinger T, Ruprecht HJ, Berger J, Bleifeld W for the German Angioplasty Bypass Surgery Investigation. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. N Engl J Med 1994; 331: 1037-43.
15. Ohman EM, Armstrong PW, Christenson RH et al for the GUSTO-IIa investigators. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med 1996; 335: 1333-41.
16. Antman EM, Tanasijevic MJ, Thompson B et al. Cardiac specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342-9.
17. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997; 337: 1648-53.
18. Elliott JM, Berdan LG, Holmes DR et al. One-year follow up in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT I). Circulation 1995; 91: 2158-66.
19. Topol EJ, Ferguson JJ, Weisman HF et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta-3 blockade with percutaneous coronary intervention. JAMA 1997; 278: 479-84.
20. Anderson KM, Califf RM, Ferguson JJ, Miller DP, Neumann FJ, Willerson JT, Weisman HF, Topol EJ. Long-term Mortality Benefit with Abciximab in Patients Undergoing Percutaneous Coronary Intervention. (Submitted for publication).
21. Tardiff BE, Califf RM, Tcheng JE et al. for the IMPACT-II investigators. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. J Am Coll Cardiol 1999; 33: 88-96.